Stay updated with breaking news from Sciences Corp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Exact Sciences Co. (NASDAQ:EXAS – Get Rating) – Equities researchers at William Blair boosted their Q2 2023 earnings per share (EPS) estimates for Exact Sciences in a report issued on Tuesday, May 16th. William Blair analyst A. Brackmann now forecasts that the medical research company will post earnings per share of ($0.46) for the quarter, […]
Exact Sciences makes molecular diagnostic tests for the early detection of colorectal and other cancers. Its flagship product is Cologuard, a stool-ba
Exact Sciences (NASDAQ:EXAS – Get Rating) had its target price raised by Piper Sandler from $70.00 to $80.00 in a report issued on Monday, The Fly reports. Piper Sandler’s price target would indicate a potential upside of 0.08% from the company’s previous close. EXAS has been the subject of a number of other research reports. […]
Diagnostic and cancer test products provider Exact Sciences Corp. (NASDAQ:EXAS) saw its shares spike over 17% on its Q1 2023 earnings results.
Principal Financial Group Inc. lifted its stake in shares of Exact Sciences Co. (NASDAQ:EXAS – Get Rating) by 1,999.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 866,805 shares of the medical research company’s stock after purchasing an additional 825,515 shares during the […]